140 related articles for article (PubMed ID: 11699394)
1. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.
Decker T; Peschel C
Leuk Lymphoma; 2001 Jul; 42(3):301-7. PubMed ID: 11699394
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
4. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
Weiner GJ
Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
[TBL] [Abstract][Full Text] [Related]
8. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells.
Wu CC; Castro JE; Motta M; Cottam HB; Kyburz D; Kipps TJ; Corr M; Carson DA
Hum Gene Ther; 2003 Jun; 14(9):849-60. PubMed ID: 12828856
[TBL] [Abstract][Full Text] [Related]
9. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells.
Britigan BE; Lewis TS; Waldschmidt M; McCormick ML; Krieg AM
J Immunol; 2001 Sep; 167(5):2921-8. PubMed ID: 11509640
[TBL] [Abstract][Full Text] [Related]
10. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.
Akiba H; Satoh M; Iwatsuki K; Kaiserlian D; Nicolas JF; Kaneko F
J Invest Dermatol; 2004 Sep; 123(3):488-93. PubMed ID: 15304088
[TBL] [Abstract][Full Text] [Related]
11. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.
Krieg AM
Biochim Biophys Acta; 1999 Dec; 1489(1):107-16. PubMed ID: 10807001
[TBL] [Abstract][Full Text] [Related]
13. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
Jahrsdörfer B; Weiner GJ
Semin Oncol; 2003 Aug; 30(4):476-82. PubMed ID: 12939716
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
Weiner GJ; Liu HM; Wooldridge JE; Dahle CE; Krieg AM
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10833-7. PubMed ID: 9380720
[TBL] [Abstract][Full Text] [Related]
16. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.
Castro JE; Prada CE; Aguillon RA; Kitada S; Fukuda T; Motta M; Wu C; Dicker F; Sun G; Wang JY; Carson DA; Reed JC; Kipps TJ
Leukemia; 2006 Apr; 20(4):680-8. PubMed ID: 16498393
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
[TBL] [Abstract][Full Text] [Related]
18. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
19. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
20. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
